Letrozole and Palbociclib in Advanced Breast Cancer: Outcome from Cancer Institute, Chennai
Year: 2020
Type: article
Study design: Observational Study
Abstract: Background: Cyclin-dependent kinase 4/6 inhibitor addition to hormonal therapy has shown to improve the survival of hormone receptor (HR)-positive, HER2-negative advanced breast cancer (ABC). Methods: We retrospectively analyzed untreated patients with HR-positive, HER2-negative ABC, who received letrozole and palbociclib at the Cancer Institute, Chennai, from October 2017 to January 2019. Results: A total of 24 patients were included in this study. The median progression-free survival (PFS) was 18 months, and the median overall survival (OS) had not reached. The 1-year PFS and OS were 73.7% and 89.2%, respectively. The common toxicities were neutropenia and fatigue but none of the patients had febrile neutropenia. Conclusion: Letrozole-Palbociclib is effective with manageable toxicity as the first-line treatment for HR-positive, HER2-negative ABC.
Authors: Vijay Gnanaguru, Manikandan Dhanushkodi, Venkatraman Radhakrishnan, Jayachandran Perumal Kalaiarasi, Nikita Mehra, Archit Joshi, Arun Kumar Rajan, Gangothri Selvarajan, Parathan Karunakaran, Balasubramanian Ananthi, Priya Iyer, Geetha Senguttuvan, Manjula Rao, Madhu Priya, Arvind Krishnamurthy, Sridevi Velusamy, Hemanth Raj, Rama Ranganathan, Shirley Sundersingh, Krishna Kumar, Selvaluxmy Ganesarajah, Trivadi S Ganesan, Tenali Gnana Sagar
Institution: Cancer Institute (WIA)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W3036935588